ChemBriefMerck tops third-quarter estimates as Keytruda, Gardasil outperform
Merck beat Q3 earnings estimates driven by Keytruda and Gardasil sales, raising its full-year revenue forecast. Additionally, positive late-stage trial data was published for an mRNA cancer vaccine de
reuters · 2026-10-29 03:32 UTC